Table 1: Patient baseline characteristics by study group.

Patient characteristic	Guideline N=68	Intensive N=100	P-value
Age, mean (SD)	72.8 (12.3)	71.7 (15.6)	0.65
Ethnicity, n (%)			
European	50 (73.5)	83 (83)	0.43
Māori	5 (7.4)	5 (5)	
Indian	5 (7.4)	0	
Chinese	1 (1.5)	1 (1)	
Pacific	4 (5.8)	7 (7)	
Other	1 (1.5)	0	
Unknown	2 (2.9)	0	
Female sex, n (%)	25 (37)	36 (36)	0.92
Hypertension, n (%)	40 (58.8)	49 (49)	0.21
Diabetes, n (%)	14 (20.6)	13 (13)	0.19
Atrial fibrillation, n (%)	18 (26.5)	24 (24)	0.72
Anticoagulation, n (%)	5 (7.4)	7 (7)	0.93
SBP pre-thrombolysis, median (range)	159 (109–212)	156 (102–241)	0.79
mRS prior to admission, median (range)	0 (0–4)	0 (0–5)	0.22
NIHSS at presentation, median (range)	9 (2–30)	9 (0–30)	0.96

Standard deviation = SD; systolic blood pressure = SBP; modified Rankin Score = mRS; National Institutes of Health Stroke Scale = NIHSS.

Table 2: Blood pressures and patient outcomes by study group.

	Intensive N=100	Guideline N=68	Odds ratio (95% confidence interval)	Adjusted odds ratio§ (95% confidence interval)	P-value
SBP >200, n (%)	23 (23)	16 (24)	0.97 (0.47–2.01)	0.97 (0.46–2.01)	0.96
SBP >180†, n (%)	**46 (46)**	**40 (59)**	**0.60 (0.32–1.11)**	**0.61 (0.32–1.17)**	**0.14**
SPB >160, n (%)	73 (73)	51 (75)	0.90 (0.45–1.82)	0.94 (0.44–2.01)	0.87
SBP <140, n (%)	98 (98)	64 (94)	3.01 (0.55–17.2)	2.7 (0.47–15.8)	0.27
SBP <120, n (%)	81 (81)	40 (59)	2.99 (1.49–5.98)	3.09 (1.49–6.40)	0.002
SBP <100, n (%)	22 (22)	10 (15)	1.64 (0.72–3.72)	1.69 (0.73–3.90)	0.22
>50% drop in SBP, n (%)	89 (89)	65 (96)	3.06 (0.55–17.2)	2.97 (0.78–11.3)	0.11
Patients given infusion, n (%)	46 (46)	21 (31)	1.91 (0.10–3.64)	2.04 (1.05–3.99)	0.04
sICH at 24 hours, n (%)	4 (4.0)	3 (4.4)	0.9 (0.20–4.17)	1.26 (0.26–6.27)	0.76
mRS 0–2 at 3-months, n (%)	55 (55)	38 (56)	1.00 (0.54–1.87)	1.27 (0.58–2.80)	0.56
mRS 0–1 at 3-months, n (%)	37 (37)	28 (41)	0.84 (0.45–1.58)	0.69 (0.32–1.52)	0.36

Systolic blood pressure = SBP; symptomatic intracerebral haemorrhage = sICH; modified Rankin Score = mRS.
†Primary study outcome.
§Model adjusted for age, premorbid mRS and National Institutes of Health Stroke Scale at presentation.
Wilcoxon Rank-Sum test p=0.93—see Figure 1 for mRS distribution.

Figure 1: Three-month modified Rankin Score Grotta chart (median [interquartile range] intensive: 2 (1–4), guideline: 2 (0–4); Wilcoxon Rank-Sum: p=0.93).

Table 3: Additional exploratory analyses.

	sICH		mRs 0–2 at 3 months	
Across entire cohort[*]	aOR (95% CI)	P-value	aOR (95% CI)	P-value
Number of >180mmHg events	1.25 (1.01–1.5)	0.01	0.85 (0.73–0.99)	0.04
Number of >185mmHg events	1.30 (1.01–1.59)	0.009	0.72 (0.56–0.93)	0.01
>50% drop in SBP (variability)	5.46 (0.82–36.4)	0.08	0.69 (0.18–2.7)	0.59
SBP at presentation	0.98 (0.95–1.02)	0.37	1.02 (0.99–1.04)	0.07
Added to study group model (aOR for intensive vs guideline group)[**]				
Number of >180mmHg events	3.4 (0.43–26.7)	0.25	0.83 (0.34–2.01)	0.68
Number of >185mmHg events	3.6 (0.43–29.8)	0.24	0.80 (0.33–1.97)	0.63
>50% drop in SBP (variability)	1.07 (0.21–5.5)	0.94	1.07 (0.45–2.56)	0.88
SBP at presentation	0.91 (0.16–5.01)	0.92	0.89 (0.37–2.15)	0.79

Symptomatic intracerebral haemorrhage = sICH; modified Rankin Score = mRS; adjusted odds ratio = aOR; confidence interval = CI; systolic blood pressure = SBP.
All models include age, pre-morbid mRS and National Institutes of Health Stroke Scale at presentation; *here, model also includes the variable listed for which the aOR is reported while study group was removed; **here, study group is included as well as the variable listed in far left column, and the aOR is reported for the intensive group compared with the guideline group.